AxoGen, Inc. (AXGN) AI Stock Analysis

AxoGen, Inc. develops and markets surgical solutions to repair physical damage or transection of peripheral nerves. Its core products include the Avance Nerve Graft, an off-the-shelf biologically active human nerve allograft designed to bridge severed nerves without a second surgical site. It also provides the AxoGuard line—comprising the Nerve Connector, Nerve Protector, and Nerve Cap made from porcine submucosa extracellular matrix—to facilitate repair, prevent soft tissue attachments, and reduce neuroma risks. In addition, AxoGen supplies the Avive Soft Tissue Membrane and the AxoTouch Two-Point Discriminator for measuring skin innervation density. Its solutions are utilized in hospitals, surgery centers, and military hospitals.

AxoGen grew revenue from $127.4M in FY2021 to $225.2M in FY2025, representing a 5-year compound annual growth rate of 14.9%. Revenue growth accelerated to 20.2% in FY2025, up from 17.8% in FY2024. However, gross margin softened from 82.0% in FY2021 to 74.3% in FY2025. Operating margin improved from -20.0% in FY2021 to -3.5% in FY2025, while net income stood at -$15.7M compared to -$10.0M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue grew 23.1% year-over-year, while trailing twelve-month revenue reached $251.2M with a net profit margin of -13.4%.

As of June 30, 2026, AxoGen held $94.6M in cash and short-term investments alongside total debt of $20.1M, yielding a net cash position of $74.5M. Liquidity remains supported by a current ratio of 6.60 and a low debt-to-equity ratio of 0.08 against shareholders' equity of $256.3M. In FY2025, the company generated $812,000 in operating cash flow and invested $3.7M in capital expenditures, leading to free cash flow of -$2.9M. Over the last five years, the company's share count expanded by 28.6%.

AxoGen trades at a forward P/E of 102.0x, a price-to-sales multiple of 8.1x, and an EV-to-revenue multiple of 9.8x. These metrics represent a premium compared to the median of its US-listed Healthcare peers, which post a forward P/E of 17.3x and a price-to-sales ratio of 4.1x. Over the past year, AxoGen delivered a 106.8% return, substantially ahead of the 16.8% return from the S&P 500 (SPY). Over a 5-year span, the stock gained 154.2% versus 83.0% for the S&P 500.

Wall Street sentiment is positive, with 9 Strong Buy ratings, 3 Buy ratings, and no Hold or Sell recommendations. The mean price target is $53.55, representing a 54.7% upside compared to the October 16, 2026 closing price of $34.62. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $0.48 on revenue of $285.6M. The company has beaten EPS expectations in 3 of the last 4 quarters, and its next earnings release is scheduled for October 28, 2026.

This page is an AI-written research summary of AxoGen, Inc. (AXGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AXGN income statement, AXGN balance sheet, AXGN key metrics, AXGN analyst forecast, AXGN chart. See the AXGN stock overview for the latest quote and news.